Common Contracts

Asset Purchase Agreement by and between ICAGEN, INC. CERTAIN SUBSIDIARIES OF ICAGEN INC. and ADJACENT ACQUISITION CO., LLC FEBRUARY 11, 2020

Asset Purchase Agreement • May 8th, 2020 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  May 8th, 2020
• Company
  Ligand Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

Asset purchase agreement

Asset Purchase Agreement • February 19th, 2020 • Icagen, Inc. • Services-commercial physical & biological research • Delaware

• Contract Type
  Asset Purchase Agreement
• Filed
  February 19th, 2020
• Company
  Icagen, Inc.
• Industry
  Services-commercial physical & biological research
• Jurisdiction
  Delaware

This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of February 11, 2020, is made and entered into by and between Icagen, Inc. (“Parent”), a Delaware corporation, Icagen Corp., a Nevada corporation, XRPro Sciences, Inc., a Delaware corporation, and Caldera Discovery, Inc., a Delaware corporation, (each, a “Subsidiary”, and the Subsidiaries, together with Parent, collectively referred to as “Seller”), and Adjacent Acquisition Co., LLC a Delaware limited liability company (“Buyer”).